Molecular biology
'Upcycling pathology': targeted next-generation sequencing is feasible in re-purposed haematoxylin and eosin and immunostained formalin-fixed paraffin-embedded sections in lung cancer biopsies
Summary
Lung cancer biopsies often yield limited material, complicating predictive molecular testing and sometimes necessitating re-biopsy. This study investigated the feasibility of repurposing routine diagnostic slides, specifically H&E-stained and immunostained sections, for molecular analysis. From 40 lung biopsy specimens, DNA extraction and targeted next-generation sequencing were successfully performed for 33 cases. The results demonstrated high concordance of detected variants, suggesting this approach is a viable alternative for molecular testing.
Critical appraisal
Clinical. This retrospective feasibility study proposes an innovative solution for lung cancer cases where biopsy material is insufficient for predictive molecular testing. By avoiding re-biopsy, it could reduce diagnostic delays, patient risks, and associated costs, thereby improving patient management. The biomarker here is a predictive marker (molecular variants). If validated on a larger scale, this approach could be integrated into clinical workflows within 3 to 5 years, especially for small biopsies.
Molecular biology. The key discovery is the technical feasibility of DNA extraction and targeted next-generation sequencing (NGS) from FFPE sections already used for diagnosis (H&E-stained or immunostained). Although DNA quality was suboptimal, the method yielded concordant sequencing results in 82.5% of cases. This approach represents a significant translational advance, allowing for the maximization of precious and limited sample material, and could lead to the development of new clinical testing protocols for lung cancer patients.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology